On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company’s combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine. The hold was placed following a “serious adverse event of motor neuropathy” that occurred in a CIC Phase 2 trial participant outside the U.S., who received the vaccine in January of 2023.
Following this news, NVAX’s stock price fell by $2.18 per share, or approximately 17% in premarket trading.
To receive more information, please fill out the form.
